Prostate Cancer Clinical Trials in Detroit

Showing 341-360 of 408 trials

Randomized Trial of Suicide Gene Therapy and Prostate Cancer

NCT00583492

This is a randomized, controlled trial that will test the hypothesis that replication-competent adenovirus-mediated suicide gene therapy in combination with 80 Gy intensity modulated radiotherapy (IRMT)will improve freedom from failure (FFF) relative to 80 Gy IMRT alone in patients with newly-diagnosed prostate cancer with an intermediate-risk profile.

Prostate Cancer

Henry Ford Health System44 participantsStarted Dec 2007

Baltimore, Maryland, United States • Detroit, Michigan, United States

COMPLETEDPhase 3< 1 mile

Radiation Therapy in Treating Patients With Bone Metastases From Breast or Prostate Cancer

NCT00003162

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known which radiation therapy regimen is more effective for bone metastases. PURPOSE: Randomized phase III trial to compare different radiation therapy regimens in treating patients who have bone metastases from breast or prostate cancer.

Breast CancerMetastatic CancerPain+1 more

Radiation Therapy Oncology Group949 participantsStarted Feb 1998

Birmingham, Alabama, United States • Huntsville, Alabama, United States • Huntsville, Alabama, United States +250 more locations

Randomized Trial of Suicide Gene Therapy and Prostate Cancer

Radiation Therapy in Treating Patients With Bone Metastases From Breast or Prostate Cancer

Prostate Cancer Trials in Other Cities

Prostate Cancer: Family Care for Patients and Spouses

A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies

Standard Therapy With or Without Dalteparin in Treating Patients With Advanced Breast, Lung, Colorectal, or Prostate Cancer

A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate Cancer

Sildenafil in Treating Erectile Dysfunction in Patients With Prostate Cancer

Tetrathiomolybdate in Hormone Refractory Prostate Cancer

Early Assessment of Treatment Response Using Functional Diffusion Mapping

Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy

Immediate Versus Deferred Androgen Deprivation Therapy,Goserelin for Recurrent Prostate Cancer After Radical Radiotherapy

Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen

Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate Cancer

Implant and External Radiation for Prostate Cancer With or Without Hormonal Therapy: A Prospective Randomized Trial

Low Dose Supplemental External Radiation With Pd-103 Versus Pd-103 Alone for Prostate Cancer

Ketoconazole, Hydrocortisone and Dutasteride in Asymptomatic Hormone Refractory Prostate Cancer

Se-Methyl-Seleno-L-Cysteine or Selenomethionine in Preventing Prostate Cancer in Healthy Participants

A Phase II Study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM With GM-CSF in Patients With PSA Progression After Local Therapy for Prostate Cancer

Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer

Study of ILX651 in Patients With Hormone-Refractory Prostate Cancer Previously Treated With Docetaxel

Other Conditions in Detroit